Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.
Press releases published on May 9, 2025
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
GlobeNewswire
·
May 9, 2025
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief …
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
GlobeNewswire
·
May 9, 2025
OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual …
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the …
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
May 9, 2025
Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new …
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND filing …
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
GlobeNewswire
·
May 9, 2025
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently …
Aya Gold & Silver Reports April Production as Zgounder Ramp Up Gains Momentum
GlobeNewswire
·
May 9, 2025
MONTREAL, May 09, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to report continued operational progress at its Zgounder Silver Mine, driven by a strong mine ramp up, exceptional mill …
Bitdeer Announces April 2025 Production and Operations Update
GlobeNewswire
·
May 9, 2025
SINGAPORE, May 09, 2025 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining, today announced its unaudited mining and operations updates for April 2025. …
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
GlobeNewswire
·
May 9, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
GlobeNewswire
·
May 9, 2025
Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4% Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% …
Castellum, Inc. Reports First Year-Over-Year Organic Revenue Growth with Q1 2025 Results
GlobeNewswire
·
May 9, 2025
VIENNA, Va., May 09, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. ("Castellum" or the "Company") (NYSE-American: CTM), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces certain highlights of its …
Outbrain Announces First Quarter 2025 Results
GlobeNewswire
·
May 9, 2025
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Outbrain Inc. (Nasdaq: OB), which is operating under the new Teads brand following Outbrain’s acquisition of Teads in February 2025, announced today financial results for the quarter ended March 31, 2025. First …
Gravity Reports First Quarter of 2025 Results and Business Update
GlobeNewswire
·
May 9, 2025
Seoul, South Korea, May 09, 2025 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games based in South Korea, today announced its unaudited financial results for the first …
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
GlobeNewswire
·
May 9, 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented …
Artax Biopharma presents Phase 2a results for oral Nck modulator AX-158 in late-breaking session at the Society for Investigative Dermatology 2025 Annual Meeting
GlobeNewswire
·
May 9, 2025
First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements in Phase 2a in patients with …
Rectify Pharma Presents Translational Data for Novel Positive Functional Modulator Demonstrating Improved Biliary and Liver Health at EASL 2025
GlobeNewswire
·
May 9, 2025
Oral dual-targeted ABCB4/BSEP positive functional modulator (PFM) improved cholestatic and cholangitis markers in orthogonal models of hepatobiliary disease Data reinforce the potential of this differentiated mechanism of action (MOA) to address the core …
Outdoor Holding Company Announces Preferred Stock Dividend
GlobeNewswire
·
May 9, 2025
SCOTTSDALE, Ariz., May 09, 2025 (GLOBE NEWSWIRE) -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“Outdoor Holding Company,” “OHC,” or the “Company”) the owner of GunBroker.com, the largest online marketplace serving the firearms and shooting sports …
Florida Governor Ron DeSantis Joins Olympia Pharmaceuticals in Ribbon-Cutting Ceremony for New Sister Pharmacy, Wesley Pharmaceuticals
GlobeNewswire
·
May 9, 2025
ORLANDO, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- Wesley Pharmaceuticals, a state-of-the-art 503B compounding facility and Olympia Pharmaceuticals' new sister brand, proudly celebrated its grand opening with a ribbon-cutting ceremony and facility tour at its …
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 9, 2025
Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to …
XRP News: Don’t Miss The $VLT Presale as Vaultro Finance Aims to Become the S&P 500 of Crypto
GlobeNewswire
·
May 9, 2025
SINGAPORE, May 09, 2025 (GLOBE NEWSWIRE) -- Crypto analysts and early DeFi backers are urging investors to pay close attention as Vaultro Finance officially launches the $VLT token presale. As the first decentralized index fund protocol built on the XRP …